Endpoints News – Biotech and pharma business news, with a focus …
A decade after Bristol Myers Squibb first won approval for its PD-1 checkpoint inhibitor Opdivo, the cancer drug has been approved in a subcutaneous form that's becom ...
Endpoints at #JPM25 - January 13-14, 2025 - San Francisco
In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather to chart the course for 2025 and take stock of the landscape, both financial and political.
Special report 2024: Meet 20 women breaking new ground in …
Oct 7, 2024 · Dedicated to the memory of Natalie Grover, who co-created the Women in Biopharma R&D special report while she was a reporter at Endpoints from 2018-2020. Natalie passed away earlier ...
News – Endpoints News
reset password. We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours. email
FogPharma rebrands as Parabilis, highlighting next drugs
Oct 28, 2024 · FogPharma is renaming itself as Parabilis Medicines, announcing a new corporate identity Monday that reflects the imprint left by CEO Mathai Mammen since joining in 2023. The name change is ...
ESMO23 | Cancer breakthroughs and barriers in oncology R&D
Endpoints is on the ground at ESMO this year and the lineup will be one to watch — what drugs in the cancer pipeline show promise? Which ones won’t make it past the goal line? Join us as we break down the highlights and readouts with our expert roundtable moderated by Endpoints journalists and more. Tune in online as our team reports from …
Subscribe - Endpoints News
Essential biopharma news and analysis Independent journalism since 2016. Our mission is to deliver the best news product in biopharma and become an essential read for industry leaders across the ...
Endpoints Careers - Find your next biopharma job
New benefit for Enterprise subscribers. All companies with an Enterprise subscription to Endpoints News will now receive two spotlight job postings per year at no charge.Contact your company subscriptions manager or DeAna ([email protected]) for more information.. For sales inquires or package requests, connect with Meg at [email protected].
J&J folds cardiovascular and metabolic drug unit
Sep 25, 2024 · Johnson & Johnson is winding down its pharma division’s cardiovascular and metabolic unit, Endpoints News has learned. The decision primarily impacts the ...
Endpoints at #BIO23: The dawn of a new biotech era
The dawn of a new biotech era. The biotech industry’s annual trade conference is back in Boston. We assess where we are as an industry and break down the future trends in biopharma.